OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Gastrobase.it

Due to the lack of prospective randomized data for the management of liver metastases from breast cancer, and the existence of several locoregional techniques, local therapy of liver metastases should ...


As predicted by their DNA-damaging mechanism of action, Platinum compounds are expected to be particularly active in tumours deficient of mechanisms responsible for DNA damage repair, e.g. those witho ...


LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with lower incidence in countries with established screening programmes but ...


A new breast cancer vaccine candidate, ( GP2 ), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it ...


Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. Researchers have assessed the efficacy and safety of the aroma ...


Results from the phase III clinical trial of the investigational drug PB272 ( Neratinib ) for the extended adjuvant treatment of breast cancer ( ExteNET Trial ). The ExteNET trial is a double-blind, ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. A stud ...


A retrospective analysis has compared the survival rates of women with BRCA associated breast cancer who did and did not undergo mastectomy of the contralateral breast. Participants were 390 women ...


A study has determined factors influencing long term risks for acquiring or dying from invasive cervical or vaginal cancer in women previously treated for cervical intraepithelial neoplasia grade 3 ( ...


False-positive results raise suspicion for breast cancer and lead to further testing, such as additional imaging or biopsy, but do not result in a cancer diagnosis. Recent evidence from the Breast ...


Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, Trastuzumab, and a Platinum s ...


Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. TH3RESA trial has compared Trastuzumab E ...


The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients ...


The findings of a large international prospective study published in the Journal of Clinical Oncology ( JCO ) suggest for the first time that women with BRCA1 mutations should have preventive ovarian ...


Pfizer has announced that the randomized Phase 2 trial, PALOMA-1, of Palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pro ...